Updated recommendations for osteoporosis treatment according to fracture risk: 2026 revision by the Swiss Association against Osteoporosis (SVGO)
Swiss Medical Weekly · 2026
DOI: 10.57187/5700 ↗Kurz gefasst
Fachartikel in der Zeitschrift Swiss Medical Weekly, 2026. Verfasst von Serge Ferrari und 6 weiteren Autor:innen. Beteiligte Einrichtung: Service des Maladies Osseuses, Department of Medicine, Geneva University Hospital (HUG) and Faculty of Medicine, Switzerland. Hauptthemen laut MEDLINE: Osteoporosis, Bone Density Conservation Agents, Osteoporotic Fractures. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Osteoporosis remains a major public health burden in Switzerland and is still associated with a substantial treatment gap. These updated recommendations from the Swiss Association against Osteoporosis (SVGO) revise the 2020 risk-based framework by integrating advances in fracture-risk assessment, lifestyle management, anabolic therapy, treatment sequencing and treat-to-target concepts. Risk assessment should be based on Swiss Fracture Risk Assessment Tool (FRAX) probabilities, possibly refined by a FRAXplus approach. Five risk categories are retained – low, moderate, high, very high and imminent risk. Patients at imminent or very high risk should preferentially receive an anabolic-first strategy followed by antiresorptive consolidation. Within the anabolic class, romosozumab and abaloparatide may be preferred when the fastest and broadest bone mineral density (BMD) gain is needed, particularly at the hip. In high-risk patients, potent antiresorptives, i.e. bisphosphonates or denosumab, remain first line. In moderate-risk patients, lifestyle optimisation remains mandatory, and raloxifene or oral bisphosphonates are usually recommended, but in selected women with osteopenia or early osteoporosis, infrequent zoledronate emerges as a pragmatic preventive option. A treat-to-target concept based primarily on hip BMD is proposed, with reassessment after 2 years and treatment sequence chosen according to baseline BMD and urgency of fracture-risk reduction. These recommendations aim to improve implementation of fracture prevention in Switzerland while acknowledging reimbursement constraints and areas where evidence remains indirect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Service des Maladies Osseuses, Department of Medicine, Geneva University Hospital (HUG) and Faculty of Medicine, Switzerland.
- Centre interdisciplinaire des Maladies Osseuses, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
- School of Health Sciences, HES-SO Valais-Wallis, University of Applied Sciences and Arts Western Switzerland, Visp, Switzerland.
- Department of Geriatrics, Universität Basel, Basel, Switzerland; Swiss Campus for Healthy Longevity, University of Basel, Basel, Switzerland.
- Department Endocrinology, Diabetes and Metabolism, University Hospital Basel, University of Basel, Basel, Switzerland.
Zitieren
APA
Ferrari, S., Biver, E., Gonzalez-Rodriguez, E., Kistler-Fischbacher, M., Lamy, O., Bischoff-Ferrari, H., & Meier, C. (2026). Updated recommendations for osteoporosis treatment according to fracture risk: 2026 revision by the Swiss Association against Osteoporosis (SVGO). Swiss Medical Weekly. https://doi.org/10.57187/5700
Vancouver
Ferrari S, Biver E, Gonzalez-Rodriguez E, Kistler-Fischbacher M, Lamy O, Bischoff-Ferrari H, et al. Updated recommendations for osteoporosis treatment according to fracture risk: 2026 revision by the Swiss Association against Osteoporosis (SVGO). Swiss Medical Weekly. 2026. doi:10.57187/5700
BibTeX
@article{Ferrari2026,
author = {Ferrari, Serge and Biver, Emmanuel and Gonzalez-Rodriguez, Elena and Kistler-Fischbacher, Melanie and Lamy, Olivier and Bischoff-Ferrari, Heike and Meier, Christian},
title = {Updated recommendations for osteoporosis treatment according to fracture risk: 2026 revision by the Swiss Association against Osteoporosis (SVGO)},
journal = {Swiss Medical Weekly},
year = {2026},
doi = {10.57187/5700}
}
EUVIMED